<DOC>
	<DOC>NCT00881569</DOC>
	<brief_summary>This is a study of CS-7017 designed to allow subjects who completed participation in a clinical study of CS 7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Subjects who have not progressed while receiving CS-7017 will continue to benefit from longer administration of the agent.</brief_summary>
	<brief_title>Extended Use Protocol for Subjects With Cancer to Receive Continued Treatment With CS-7017</brief_title>
	<detailed_description>This is an open-label non-randomized study of CS7017 designed to allow subjects who completed participation in a clinical study of CS7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug.</detailed_description>
	<mesh_term>Efatutazone</mesh_term>
	<criteria>Subject previously treated with CS7017 as part of a study that included CS7017 and has shown clinical benefits from treatment with CS7017. Anticipation of need for a major surgical procedure or radiation therapy during the study. Any of the following conditions within 6 months prior to initiating study treatment: Myocardial infarction with significant impairment of cardiac function (eg, ejection fraction â‰¤ 50%), severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class II or higher congestive heart failure. Subjects with clinically significant pleural or pericardial effusions. Clinically significant active infection, which requires antibiotic therapy, or HIVpositive subjects receiving antiretroviral therapy. Subjects with diabetes mellitus requiring treatment with insulin, sulfonylureas or TZDs agents, malabsorption syndrome, chronic diarrhea, inflammatory bowel disease, or partial bowel obstruction.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>